US 12157891
Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
granted A61PA61P27/02
Quick answer
US patent 12157891 (Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61P, A61P27/02